22MJ image
Deposition Date 2026-01-16
Release Date 2026-03-11
Last Version Date 2026-04-15
Entry Detail
PDB ID:
22MJ
Keywords:
Title:
Crystal structure of human INPP5K with an allosteric inhibitor reveals the structural basis for species specific potency
Biological Source:
Source Organism(s):
Homo sapiens (Taxon ID: 9606)
Expression System(s):
Method Details:
Experimental Method:
Resolution:
1.90 Å
R-Value Free:
0.24
R-Value Work:
0.22
R-Value Observed:
0.23
Space Group:
P 32 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Inositol polyphosphate 5-phos
Gene (Uniprot):INPP5K
Chain IDs:A
Chain Length:322
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Crystal structure of human INPP5K with an allosteric inhibitor reveals the structural basis for species specific potency.
Sci Rep 16 ? ? (2026)
PMID: 41748720 DOI: 10.1038/s41598-026-40748-4

Abstact

Inositol polyphosphate 5-phosphatase K (INPP5K) is a phosphatidylinositol (3,4,5)-trisphosphate phosphatase that increases glucose uptake and regulates myogenesis in the skeletal muscle. To understand the mechanism of its species-specific inhibition, we determined the 1.9-A resolution crystal structure of human INPP5K in complex with a selective inhibitor, CPD-1 (IC(50) = 2.9 microM). The structure reveals that CPD-1 binds to a novel allosteric pocket, inducing a large conformational change in alpha-helix 3 that alters the active site and prevents substrate binding. This finding explains its unique, noncompetitive inhibitory mechanism. Crucially, while the inhibitor-binding residues are conserved, the key residue governing the allosteric transition is not conserved in mouse and rat INPP5K, which correlates with their insensitivity to CPD-1 (IC(50) > 100 microM). Based on these structural insights, we identified the hamster as a pharmacologically relevant preclinical model (IC(50) = 8.2 microM). These findings provide a structural basis for the rational design of next-generation INPP5K inhibitors and establish a suitable animal model for their evaluation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1038/s41598-026-40748-4.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback